Do Kim
Stock Analyst at Piper Sandler
(2.03)
# 3,037
Out of 5,154 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $74.04 | -14.91% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $27.24 | +68.87% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $456.69 | -35.19% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $143.93 | -22.18% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $12.74 | +582.89% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.23 | +1,769.92% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $28.87 | -30.72% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $8.07 | +432.84% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $41.55 | -22.98% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.45 | +537.68% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $45.29 | -58.05% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.59 | +248.58% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $320.66 | -42.31% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.15 | +21,586.75% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $67.37 | -48.05% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.33 | +1,403.76% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $74.04
Upside: -14.91%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $27.24
Upside: +68.87%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $456.69
Upside: -35.19%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $143.93
Upside: -22.18%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $12.74
Upside: +582.89%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.23
Upside: +1,769.92%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $28.87
Upside: -30.72%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $8.07
Upside: +432.84%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $41.55
Upside: -22.98%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.45
Upside: +537.68%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $45.29
Upside: -58.05%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.59
Upside: +248.58%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $320.66
Upside: -42.31%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.15
Upside: +21,586.75%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $67.37
Upside: -48.05%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.33
Upside: +1,403.76%